CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
6 results
Search Results
Now showing 1 - 6 of 6
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Multisite Detection of Tn
<i>1549</i>
-Mediated
<i>vanB</i>
Vancomycin Resistance in Multidrug-Resistant Enterococcus faecalis ST6 in Texas and Florida(2023) ;Shelby R. Simar ;Truc T. Tran ;Kirsten B. Rydell ;Diana PanessoGerman A. Contreras<jats:p> In the United States, <jats:italic>vanB</jats:italic> -mediated resistance in enterococci is rare. We characterized three sequence type (ST) 6, vancomycin-resistant <jats:named-content content-type="genus-species">Enterococcus faecalis</jats:named-content> isolates causing bacteremia in unique patients in spatiotemporally distinct settings. </jats:p>7 1Scopus© Citations 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Antimicrobial Susceptibility Testing for Enterococci(2022) ;Ayesha Khan ;William R. Miller ;Dierdre Axell-House; Cesar A. Arias<jats:p>Enterococci are major, recalcitrant nosocomial pathogens with a wide repertoire of intrinsic and acquired resistance determinants and the potential of developing resistance to all clinically available antimicrobials. As such, multidrug-resistant enterococci are considered a serious public health threat.</jats:p>1Scopus© Citations 57 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa(2022); ;Manuel Alcalde-Rico ;José R. W. Martínez ;María Victoria MorenoPamela Rojas<jats:p> Ceftolozane/tazbactam (C/T) is a potent anti-pseudomonal agent that has clinical utility against infections caused by non-carbapenemase, producing-carbapenem-resistant <jats:named-content content-type="genus-species">Pseudomonas aeruginosa</jats:named-content> (non-CP-CR-PA). Accurate, precise, and reliable antimicrobial susceptibility testing (AST) is crucial to guide clinical decisions. </jats:p>19Scopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Genomic Epidemiology of Vancomycin-Resistant Enterococcus faecium (VREfm) in Latin America: Revisiting The Global VRE Population Structure(2020) ;Rafael Rios ;Jinnethe Reyes ;Lina P. Carvajal ;Sandra RinconDiana Panesso<jats:title>Abstract</jats:title><jats:p>Little is known about the population structure of vancomycin-resistant <jats:italic>Enterococcus faecium</jats:italic> (VR<jats:italic>Efm</jats:italic>) in Latin America (LATAM). Here, we provide a complete genomic characterization of 55 representative Latin American VR<jats:italic>Efm</jats:italic> recovered from 1998–2015 in 5 countries. The LATAM VR<jats:italic>Efm</jats:italic> population is structured into two main clinical clades without geographical clustering. Using the LATAM genomes, we reconstructed the global population of VR<jats:italic>Efm</jats:italic> by including 285 genomes from 36 countries spanning from 1946 to 2017. In contrast to previous studies, our results show an early branching of animal related isolates and a further split of clinical isolates into two sub-clades within clade A. The overall phylogenomic structure of clade A was highly dependent on recombination (54% of the genome) and the split between clades A and B was estimated to have occurred more than 2,765 years ago. Furthermore, our molecular clock calculations suggest the branching of animal isolates and clinical clades occurred ~502 years ago whereas the split within the clinical clade occurred ~302 years ago (previous studies showed a more recent split between clinical an animal branches around ~74 years ago). By including isolates from Latin America, we present novel insights into the population structure of VR<jats:italic>Efm</jats:italic> and revisit the evolution of these pathogens.</jats:p>1Scopus© Citations 47 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Novel Strategies for the Management of Vancomycin-Resistant Enterococcal Infections(2019) ;German A. Contreras; Cesar A. Arias1Scopus© Citations 36 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A Multicenter Study To Evaluate Ceftaroline Breakpoints: Performance in an Area with High Prevalence of Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Lineage(2019) ;Ayesha Khan ;Lina M. Rivas ;Maria Spencer ;Rodrigo MartinezMarusella Lam<jats:p> Ceftaroline (CPT) is a broad-spectrum agent with potent activity against methicillin-resistant <jats:named-content content-type="genus-species">Staphylococcus aureus</jats:named-content> (MRSA). The sequence type 5 (ST5) Chilean-Cordobés clone, associated with CPT nonsusceptibility, is dominant in Chile, a region with high rates of MRSA infections. </jats:p>1Scopus© Citations 7 1